US OptionsDetailed Quotes
BSX240816C115000
- 0.00
- 0.000.00%
15min DelayTrading Jul 22 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest115.00Strike Price0.00Turnover75.49%IV47.25%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.0347Delta0.0049Gamma390.50Leverage Ratio-0.0231Theta0.0018Rho13.56Eff Leverage0.0159Vega
Boston Scientific Stock Discussion
Sign in to post a comment
The stock price of $Intuitive Surgical(ISRG.US$ , the maker of Da Vinci surgical robot system surged 9.34% after its earnings report on Friday, and its market value exceeded $160 billion.
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
Second quarter revenue of $2.01 billion increased by 14% compared with $1.76 billion in the second quarter of 2023. The second quarter GAAP net income attributable to Intuitive was $52...
+1
16
1
$Boston Scientific(BSX.US$
Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals
Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals
1
$Boston Scientific(BSX.US$
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
ColumnsOptions Market Statistics: Tesla Stock Jumps on Accelerated Production Plans Despite Earnings Miss
News Highlights
$Tesla(TSLA.US$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
$Tesla(TSLA.US$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
25
3
Insiders selling Boston Scientific shares, even below current price, is discouraging. Yet, high insider ownership could imply company's interest in all shareholders.
1
Boston Scientific's high P/E ratio is attributed to investors' optimism about its strong future growth and market outperformance. Shareholders' confidence in the company's future earnings supports the current P/E ratio and share price.
1
Boston Scientific's EPS growth and insider ownership hint at future success, but investors should note the 2 warning signs. Its strong performance makes it a company to watch.
Piper Sandler analysts find Boston Scientific, Expedia Group, Progressive Corporation, Skechers U.S.A., Synovus Financial, and Zoetis Inc. stocks attractive due to their individual strengths and positive trends.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
No comment yet
105535782 : ok